Literature DB >> 12846629

Adrenal axis testing and corticosteroid replacement therapy in septic shock patients--local and national perspectives.

R S Bourne1, S J Webber, S P Hutchinson.   

Abstract

Recently, there has been renewed interest in corticosteroid therapy for patients with septic shock. The cortisol response to a tetracosactide stimulation test, otherwise known as a short synacthen test, may identify which patients are most likely to benefit from corticosteroid replacement. Controversy over interpretation of the cortisol response and the correct tetracosactide dose remains. We retrospectively analysed all septic shock patients who had full cortisol results following a 1- micro g short synacthen test. All cortisol results were re-evaluated by three common ways of interpreting the cortisol response to a short synacthen test. The thresholds were a cortisol rise >/= 250 nmol x l(-1), a peak cortisol >/= 550 nmol x l(-1) and a peak cortisol >/= 700 nmol x l(-1). We found a significant relationship between the peak cortisol results and haemodynamic improvement in patients given corticosteroids. There was no association between a cortisol rise >/= 250 nmol x l(-1) and haemodynamic improvement after corticosteroids. A postal questionnaire was sent to adult intensive care units in the United Kingdom to assess national practice. Sixty per cent of intensive care units use corticosteroids in septic shock patients, but only 22% use a short synacthen test to guide therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846629     DOI: 10.1046/j.1365-2044.2003.03183.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  Occult Adrenal Insufficiency in Renal Amyloidosis Patients.

Authors:  Didem Turgut; Serhan Vahit Piskinpasa; Havva Keskin; Kemal Agbaht; Ezgi Coskun Yenigun; Fatih Dede
Journal:  Medeni Med J       Date:  2021-03-26

2.  Waterhouse-friderichsen syndrome in an adult patient with meningococcal meningitis.

Authors:  Viral N Shah
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.